Details

Autor(en) / Beteiligte

• Inayama, Yoshihide
• Mizuno, Kayoko
• Egawa, Miho
• Yamaguchi, Ken
• Hamanishi, Junzo
• Takeuchi, Masato
• Mandai, Masaki
• Kawakami, Koji

Titel

Real‐world practice of estrogen and progestogen prescriptions in menopausal women in Japan: A descriptive study using a Japanese claims database

Ist Teil von

• The journal of obstetrics and gynaecology research, 2023-12, Vol.49 (12), p.2952-2961

Ort / Verlag

Kyoto, Japan: John Wiley & Sons Australia, Ltd

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• Aim This study aimed to investigate the real‐world clinical practice of estrogen and progestogen prescriptions for menopausal women. Methods Using a health care database in Japan, we conducted a cross‐sectional study on estrogen prescriptions and detailed analyses of newly initiated estrogens and concomitant prescriptions of progestogens. Data between January 2005 and December 2021 were analyzed. Results In 2021, the proportion of women aged 45–49 years receiving estrogens was 25.8 [95% confidence interval (CI): 25.3, 26.3] per 1000 women, while it was 6.4 [95% CI: 6.0, 6.7] for those aged ≥60 years. The prescription of estrogens gradually increased in women aged 50–59 years after 2009. In women without a history of hysterectomy, transdermal estradiol was the primary form of estrogens prescribed for ≥180 days, in women aged <60 years. The proportion of transdermal estradiol gradually increased each year, whereas that of oral‐conjugated equine estrogens decreased. Among progestogen, the proportions of dydrogesterone and transdermal norethisterone acetate increased over time, while that of medroxyprogesterone acetate decreased. Approximately 30% of women prescribed estrogens for ≥180 days did not initiate progestogen concurrently. In women undergoing hysterectomy, progestogen was not initiated in >90% of cases, and transdermal estradiol was prescribed in approximately 80% of cases in 2021. Conclusions This study reviewed the prescription of estrogens in menopausal women in Japan. A considerable number of women with a uterus are receiving estrogen therapy rather than estrogen‐progestogen therapy (EPT), despite the guidelines recommending the use of EPT in these women.